Antonio Rodríguez

Bio: Antonio Rodríguez is an academic researcher from University of Alcalá. The author has contributed to research in topics: Infliximab & Catalysis. The author has an hindex of 15, co-authored 33 publications receiving 1347 citations.

TiO2-assisted photocatalytic degradation of azo dyes in aqueous solution: kinetic and mechanistic investigations A review

Abstract: The photocatalytic degradation of azo dyes containing different functionalities has been reviewed using TiO2 as photocatalyst in aqueous solution under solar and UV irradiation. The mechanism of the photodegradation depends on the radiation used. Charge injection mechanism takes place under visible radiation whereas charge separation occurred under UV light radiation. The process is monitored by following either the decolorization rate and the formation of its end-products. Kinetic analyses indicate that the photodegradation rates of azo dyes can usually be approximated as pseudo-first-order kinetics for both degradation mechanisms, according to the Langmuir–Hinshelwood model. The degradation of dyes depend on several parameters such as pH, catalyst concentration, substrate concentration and the presence of electron acceptors such as hydrogen peroxide and ammonium persulphate besides molecular oxygen. The presence of other substances such as inorganic ions, humic acids and solvents commonly found in textile effluents is also discussed. The photocatalyzed degradation of pesticides does not occur instantaneously to form carbon dioxide, but through the formation of long-lived intermediate species. Thus, the study focuses also on the determination of the nature of the principal organic intermediates and the evolution of the mineralization as well as on the degradation pathways followed during the process. Major identified intermediates are hydroxylated derivatives, aromatic amines, naphthoquinone, phenolic compounds and several organic acids. By-products evaluation and toxicity measurements are the key-actions in order to assess the overall process.

Explaining the Enhanced Photocatalytic Activity of Degussa P25 Mixed-Phase TiO2 Using EPR

Abstract: Charge separation characteristics of a high-activity, mixed-phase titania photocatalyst (Degussa P25) are probed by EPR spectroscopy. While previous proposals consider rutile as a passive electron sink hindering recombination in anatase, this research details the critical and active role of rutile in TiO2 formulations. The inactivity of pure-phase rutile is due in part to rapid rates of recombination. Yet, in mixed-phase TiO2, charges produced on rutile by visible light are stabilized through electron transfer to lower energy anatase lattice trapping sites. These results suggest that within mixed-phase titania (P25) there is a morphology of nanoclusters containing atypically small rutile crystallites interwoven with anatase crystallites. The transition points between these two phases allow for rapid electron transfer from rutile to anatase. Thus, rutile acts as an antenna to extend the photoactivity into visible wavelengths and the structural arrangement of the similarly sized TiO2 crystallites creates ca...

2016 updated EULAR evidence-based recommendations for the management of gout

Abstract: Background New drugs and new evidence concerning the use of established treatments have become available since the publication of the first European League Against Rheumatism (EULAR) recommendations for the management of gout, in 2006. This situation has prompted a systematic review and update of the 2006 recommendations. Methods The EULAR task force consisted of 15 rheumatologists, 1 radiologist, 2 general practitioners, 1 research fellow, 2 patients and 3 experts in epidemiology/methodology from 12 European countries. A systematic review of the literature concerning all aspects of gout treatments was performed. Subsequently, recommendations were formulated by use of a Delphi consensus approach. Results Three overarching principles and 11 key recommendations were generated. For the treatment of flare, colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids or a combination are recommended. In patients with frequent flare and contraindications to colchicine, NSAIDs and corticosteroids, an interleukin-1 blocker should be considered. In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at<6 mg/dL (360 µmol/L ) and <5 mg/dL (300 µmol/L ) in those with severe gout. Allopurinol is recommended as first-line ULT and its dosage should be adjusted according to renal function. If the SUA target cannot be achieved with allopurinol, then febuxostat, a uricosuric or combining a xanthine oxidase inhibitor with a uricosuric should be considered. For patients with refractory gout, pegloticase is recommended. Conclusions These recommendations aim to inform physicians and patients about the non-pharmacological and pharmacological treatments for gout and to provide the best strategies to achieve the predefined urate target to cure the disease.